Tactile Systems Technology, Inc.
TCMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tactile Systems Technology, Inc. focuses on Medical Devices services and products. Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. The $576.3M market capitalization puts TCMD squarely in small-cap range for its industry. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Market Cap
$576.3M
Beta
0.82
P/E (TTM)
29.37
P/E (Fwd)
16.98
EPS (TTM)
$0.87
EPS (Fwd)
$1.50
ROE
9.6%
ROA
7.3%
Cash
$75.0M
Total Debt
$15.2M
Free CF
$33.5M
52W Change
158.6%
Annual Financials
Cash vs Debt
With $75.0M in cash and $15.2M in debt, TCMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $33.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 9.6% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $246.8M (2022) to $329.5M (2025), reflecting a 34% increase over the period.
With cash comfortably exceeding debt, TCMD has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing TCMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.